FDA godkänner första behandling för barn med sällsynta sjukdomar som orsakar inflammation i små blodkärl

Rituxan (rituximab), ett välkänt läkemedel vid behandling av reumatoid artrit, fann sitt sätt att behandla sällsynt sjukdom granulomatös med polyangit (GPA, Wegeners granulomatos)

“Rituxan is now approved as the first and only medicine for paediatric patients living with GPA and MPA, two potentially life-threatening blood vessel disorders which are rare in children,” said Sandra Horning, M.D., Roche’s Chief Medical Officer and Head of Global Product Development. “Today’s approval is a result of our ongoing commitment to working with the FDA to develop medicines for paediatric patients with rare diseases where there is a serious unmet need.”